The DOE has provided funding to NorthStar Medical Radioisotopes and other companies developing alternatives to older reactor production of Moly-99. In its latest announcement, NorthStar announced it entered into an agreement with IBA to purchase up to 8-of its electron beam accelerators to produce a non-uranium based source of Moly-99. Two are already on order. Although this is not a one stop solution for the entire demand for U.S. based radiopharmaceuticals, it is a regional and supplemental initiative that will add to the inventory and support those providing nuclear medicine imaging services.
https://www.auntminnie.com/index.aspx?sec=sup&sub=roc&pag=dis&ItemID=125063